Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development
Provided By GlobeNewswire
Last update: Mar 12, 2024
NORCROSS, Ga., March 12, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of Khurram Jamil, M.D. as Vice President, Clinical Development. Dr. Jamil brings to Galectin almost two decades of experience in clinical development across the biotechnology industry.
